Inventors
Stephanie Elizabeth MACIUBA, Gregory D BOWDEN, Kazimierz A. Wisniewski, Pierre Jean-Marie RIVIERE
Assignees
Peptide Logic Llc, Reddie & Grose Llp
Abstract
An antibody or antigen-binding fragment thereof binds to human prolactin (hPRL) whilst also neutralizing its agonism of the human PRL receptor (hPRLR). Advantageously, this allows other hPRLR agonists to continue signalling. In turn, the antibody or antigen-binding fragment thereof is suitable for therapeutic use, e.g., as a composition comprising the antibody or antigen-binding fragment thereof. For example, the antibody or antigen-binding fragment thereof may be for use in the treatment of a disease or condition which is modulated by PRL, e.g., for use in the treatment of pain.
